Back to top
more

Biogen (BIIB)

(Delayed Data from NSDQ)

$173.04 USD

173.04
1,581,725

-0.88 (-0.51%)

Updated Nov 8, 2024 04:00 PM ET

After-Market: $173.02 -0.02 (-0.01%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value C Growth D Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 31% (77 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Biogen Inc. (BIIB) Stock Sinks As Market Gains: What You Should Know

by Zacks Equity Research

Biogen Inc. (BIIB) closed the most recent trading day at $266.15, moving -0.66% from the previous trading session.

Biogen Inc. (BIIB) Down 2.3% Since Last Earnings Report: Can It Rebound?

by Zacks Equity Research

Biogen Inc. (BIIB) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Biogen (BIIB) Up 29% in a Year Despite Multiple Challenges

by Zacks Equity Research

Most of Biogen's (BIIB) key drugs are facing declining sales. Despite these challenges, potential new product launches such as Leqembi (Alzheimer's disease) and zuranolone (depression) can help revive growth.

Should You Invest in the SPDR S&P Biotech ETF (XBI)?

by Zacks Equity Research

Sector ETF report for XBI

Biogen Inc. (BIIB) Gains As Market Dips: What You Should Know

by Zacks Equity Research

Biogen Inc. (BIIB) closed the most recent trading day at $262.37, moving +0.01% from the previous trading session.

Biogen Inc. (BIIB) Gains But Lags Market: What You Should Know

by Zacks Equity Research

In the latest trading session, Biogen Inc. (BIIB) closed at $262.35, marking a +1.47% move from the previous day.

Should iShares Morningstar Mid-Cap Value ETF (IMCV) Be on Your Investing Radar?

by Zacks Equity Research

Style Box ETF report for IMCV

Lilly's (LLY) Alzheimer Drug Fails Late-Stage Prevention Study

by Zacks Equity Research

Data from a late-stage study showed that treatment with Eli Lilly's (LLY) solanezumab did not result in the clearance of brain amyloid plaque in people with preclinical Alzheimer's disease.

Biogen Inc. (BIIB) Stock Sinks As Market Gains: What You Should Know

by Zacks Equity Research

Biogen Inc. (BIIB) closed the most recent trading day at $263.02, moving -0.7% from the previous trading session.

Biogen (BIIB), Eisai Seek Full Nod for Alzheimer Drug Leqembi

by Zacks Equity Research

The FDA grants priority review to Biogen (BIIB) and Eisai's sBLA seeking traditional approval of Alzheimer's disease drug, Leqembi. The FDA decision is expected on Jul 6, 2023.

Denali (DNLI) Q4 Earnings Beat Estimates, Pipeline in Focus

by Zacks Equity Research

Denali (DNLI) reports better-than-expected results for the fourth quarter and full-year 2022, as it beats both earnings and revenue estimates.

Ionis (IONS) Q4 Earnings Top Estimates, Sales Lag, Stock Down

by Zacks Equity Research

Ionis (IONS) Q4 loss is narrower than expected. However, sales miss estimates. Revenue guidance for 2023 looks soft. Stock down.

Sanghamitra Saha headshot

How Are Biotech ETFs Reacting to Q4 Earnings Releases?

by Sanghamitra Saha

The latest earnings from some of the big biotech players came in at mixed this reporting season.

Biotech Stock Roundup: BIIB's Q4 Results, EBS and BPMC Offer Updates

by Zacks Equity Research

Earnings results from Biogen (BIIB) and updates from EBS are the key highlights from the biotech sector during the past week.

Compared to Estimates, Biogen Inc. (BIIB) Q4 Earnings: A Look at Key Metrics

by Zacks Equity Research

Although the revenue and EPS for Biogen Inc. (BIIB) give a sense of how its business performed in the quarter ended December 2022, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Biogen (BIIB) Beats Q4 Earnings & Sales Estimates, Stock Up

by Zacks Equity Research

Biogen (BIIB) beats fourth-quarter estimates for earnings and sales. Stock rises in pre-market.

Biogen Inc. (BIIB) Q4 Earnings and Revenues Beat Estimates

by Zacks Equity Research

Biogen Inc. (BIIB) delivered earnings and revenue surprises of 15.38% and 4.13%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Should BNY Mellon US Mid Cap Core Equity ETF (BKMC) Be on Your Investing Radar?

by Zacks Equity Research

Style Box ETF report for BKMC

AbbVie (ABBV) Beats Q4 Earnings Estimates, Misses on Sales

by Zacks Equity Research

AbbVie's Q4 earnings (ABBV) beat estimates, while sales miss the same. Full-year 2023 EPS falls short of estimates.

Biogen Inc. (BIIB) Reports Next Week: Wall Street Expects Earnings Growth

by Zacks Equity Research

Biogen Inc. (BIIB) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Will Biogen (BIIB) Beat Estimates This Earnings Season?

by Zacks Equity Research

Biogen's (BIIB) sales in the fourth quarter are likely to have been hurt by lower sales of Tecfidera and Spinraza.

Sage and Biogen's NDA for Depression Drug Gets Priority Review

by Zacks Equity Research

Sage Therapeutics, Inc. (SAGE) and partner, Biogen Inc.'s (BIIB) NDA for zuranolone to treat adults with MDD and PPD accepted by the FDA and granted priority review.

Biogen Inc. (BIIB) Gains As Market Dips: What You Should Know

by Zacks Equity Research

Biogen Inc. (BIIB) closed at $288.28 in the latest trading session, marking a +1.64% move from the prior day.

Biogen Inc. (BIIB) Dips More Than Broader Markets: What You Should Know

by Zacks Equity Research

Biogen Inc. (BIIB) closed at $285.94 in the latest trading session, marking a -1.43% move from the prior day.

Biogen (BIIB) & Eisai's Lecanemab Secures EMA's MAA Acceptance

by Zacks Equity Research

Biogen (BIIB) and Eisai jointly announce that EMA accepts lecanemab's marketing authorization application (MAA) for the treatment of patients with early-stage Alzheimer's disease, for review.